India-Specific Consensus on MASLD in Type 2 Diabetes: Bridging Global Guidelines to Local Realities

We read with interest the recently published American Diabetes Association (ADA) consensus report on metabolic dysfunction–associated steatotic liver disease (MASLD) in type 2 diabetes (T2D) by Cusi et al. (1). While it provides a valuable global perspective, its applicability in low- and middle-income countries (LMICs) like India is limited by issues of affordability, drug access, and dietary relevance.